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ABSTRACT

OBJECTIVE: To determine whether or not pharmacotherapy is a safe and effective treatment
option for smoking cessation in adolescents
STUDY DESIGN: Review of three English language primary studies published in 2007, 2008,
and 2009
DATA SOURCES: Two Randomized double-blind placebo-controlled trials and one
Randomized Control Study comparing pharmacotherapy, including nicotine nasal spray (NNS),
Bupropion hydrochloride, and Varencline, at different doses to placebo, therapy, or both, were
found using MEDLINE, OVID, PUBMED, and COCHRANE databases.
OUTCOME MEASURED: Measurement of efficacy included self reported reduction in number
of cigarettes smoked per day, confirmed by reduction in exhaled carbon monoxide and saliva or
urine cotinine levels; seven-day point prevalence of abstinence; and self-rated addiction scale (1100%). Measurement of safety included reported incidence of side effects; degree of agreement
with statement about side effects (“Strongly agree” to “strongly disagree”)
RESULTS: Muramoto et al. showed that Bupropion hydrochloride significantly increased the
seven day point prevalence abstinence at six weeks compared to placebo (p-value = .03), but did
not significantly affect the seven day point prevalence at 26 weeks (p-value = .28). The Faessel
study highlighted a higher decrease in number of cigarettes smoked per day, but failed to include
any p-values. Rubenstein, et al. failed to show any statistical difference between the arm that
received only counseling and the arm that received counseling and NNS.
CONCLUSION: Of the three interventions used in the randomized control studies included in
this review, only Bupropion hydrochloride demonstrated significant safety and efficacy as
therapy for smoking cessation in adolescents. High relapse rate, however, necessitates that a
longer trial of Bupropion be investigated in the future.
KEYWORDS: Smoking Cessation, Adolescents, Chantix, Varencline, Bupropion hydrochloride,
Zyban, Pharmacotherapy
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Introduction
Tobacco use is the number one preventable contributor to serious morbidity and mortality
in the United States. Of particular public health concern is the number of adolescent cigarette
smokers. Over 90% of adult habitual tobacco users picked up the habit before their eighteenth
birthday. Each year, nearly 1.5 million adolescents initiate smoking and 416,000 becoming
daily smokers. In addition to an increased risk for heart disease, cancer, stroke, and associated
premature mortality, adolescent smokers disproportionately develop a host of more immediate
health consequences. These include reduced growth of lung function, persistent cough,
shortness of breath, poorer overall health, fitness, and endurance, greater involvement in high
risk behaviors, and poorer mental health. Despite increased awareness of these dangers,
cigarette smoking among high school students has remained stable since 2003. 1
Components of cigarettes and other tobacco products not only contain several harmful
carcinogenic substances, but also those that stimulate receptors in the brain that contribute to
addiction. In adolescents, signs and symptoms of addiction can present in as little as a few days
following initiation of occasional tobacco use.2 More than a quarter of children and adolescents
who tried their first tobacco product before the age of 18 develop dependency by the same age.1
Despite a high percentage of adolescent smokers who wish to quit, adolescents have the highest
cessation attempt failure compared to any other population. Even with the help of nonpharmacologic interventions, the increase in successful cessation is statistically insignificant.3
Current first line medications for smoking cessation in adults include nicotine
replacement therapies (transdermal patch, nasal spray, inhaler, gum), Bupropion hydrochloride
(Zyban), and Varencline (Chantix). First line agents have been shown to double the success rate
of quitting in this population. Norytriptiline and clonidine are considered second line agents and
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are not FDA approved for this purpose. Neither first nor second line agents, however, are FDA
approved for the use in adolescent populations. Since most regular users start before age 18 and
quickly become addicted, and the longer a person smokes the greater the risk of morbidity and
premature mortality, it seems imperative that more intensive treatments for tobacco cessation be
evaluated for the adolescent population.
Objective
The objective of this systematic review is to determine whether or not pharmacotherapy
is a safe and effective treatment option for smoking cessation in adolescents.
Methods
A search for randomized control trials was conducted by the author via MEDLINE,
OVID, PUBMED, and COCHRANE databases. Keywords utilized included Smoking Cessation,
Adolescents, Chantix, Varencline, Bupropion hydrochloride, Zyban, Pharmacotherapy, and
Nicotine Replacement Therapy (NRT). Only studies published in English in peer reviewed
journals were considered for inclusion. In addition, a search was conducted in order to ensure
that no Meta Analysis or Systematic Review of the topic of focus existed.
The three studies included in this review are randomized control trials that compare the
use of different medications (Bupropion, Varencline, and Nicotine Nasal Spray) for smoking
cessation in adolescents to either a placebo, therapy, or a combination of the two. All subjects
were between the ages of twelve and eighteen, smoked at least three cigarettes a day, were not
currently (or recently) on another pharmacologic agent for smoking cessation, and were
otherwise healthy. More specific inclusion and exclusion criteria can be found in Table 1.
Results of these studies were evaluated based on patient oriented outcomes. Reported statistics
included p-value, RBI, ABI, NNT, mean change from baseline.
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Table 1: Demographics of Included Studies
Characteristics of Studies Included in Systematic Review of Safety and Efficacy of Pharmacotherapy
for Adolescent Smoking Cessation
Study
Type
# of Age in Inclusion
Exclusion Criteria
W/D Interventions
Pts
yrs
Criteria
Faessel,
RCT
42
12-16 Smoke > 3
Regular EtOH/illicit
1
Varencline 1
USA, 2009
double
cigarettes/d drug use
mg BID x 14
-blind
Otherwise
Crcl <80 mL/min
days
healthy
Donation >280 mL
blood within last 56 d
Sensitivity to heparin
or hx of HIT
Use of meds other
than acetaminophen
in last 7 days
Tx with
investigational drug
in last 30 days
Rubinstein,
USA, 2008

RCT

40

15-18

Smoke >5
cigarettes/d
for > 5
months
Want to quit
smoking

Previous/current use
of nicotine
replacement therapy
Use of Bupropion
hydrochloride in last
30 days

8

Muramoto,
USA, 2007

RCT
double
-blind

207

14-17

Smoke < 6
cigarettes/ d
Exhaled CO
> 10 ppm
At least 2
previous
quit
attempts

Current use of other
Tobacco products, or
smoking cessation
therapies
Current ADHD,
depression, or other
psychiatric disorder
Use of psychoactive
drug in last 4 weeks
Significant CVD dz
or risk of seizure
Pregnancy or refusal
to use contraceptives

92

Nicotine
Nasal Spray
1mg (4
sprays) PRN
(not to exceed
40/d) x 6 wks
w/ counseling
before (2
wks), and
during
SR Bupropion
300mg/d with
brief
counseling for
6 weeks
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Outcomes Measured
The efficacy of the tobacco cessation treatment was determined by reduction in use and
desire to use tobacco products. Muramoto et al. focused on successful cessation of cigarette
smoking. In this study, the seven day point prevalence of abstinence was calculated at various
times throughout the study based on self reported cessation. Self report was confirmed by either
exhaled carbon monoxide or urine cotinine levels. An exhaled carbon monoxide level of less
than 10 ppm and a urine cotinine level of less than or equal to 50 microg/L are consistent with at
least seven days of abstinence. Faessel et al. focused on reduction of the average number of
cigarettes smoked per day by the end of the trial as measurement of efficacy of Varencline.
Rubenstein et al. also measured the mean reduction of cigarettes smoked per day, but in addition
used a self reported scale of addiction as measurement of the efficacy of nicotine nasal spray.
Safety of the different pharmacotherapy was determined by the number of subjects
reporting side effects with the intervention of interest compared to the number of subjects
reporting side effects on the placebo. No placebo was used in the Nicotine Nasal Spray trial,
however, and therefore no comparison was possible.
Results
All studies analyzed in this review were randomized control trials, two of which were
double-blind, focused on patient oriented outcomes in an adolescent population of cigarette
smokers, smoking at least three cigarettes per day. Each study met the inclusion criteria as listed
above.
In the Muramoto study, participants were split into three groups, one that received a
placebo, one that received 150mg Bupropion hydrochloride, and one that received 300mg
Bupropion hydrochloride. All groups also received counseling for the six weeks during which
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the medication was given. The most significant difference was found between the group that
received the placebo and the group that received the higher dose of Bupropion hydrochloride.4
For the purpose of this paper, only the dichotomous data from these two groups was analyzed.
Table 2 shows the seven day point prevalence abstinence at six and twenty-six weeks after the
target quit date. At six weeks, 5 out of 89 of those in the placebo group and 12 out of 83 in the
treatment group, had not smoked a cigarette in seven days (confirmed by a urine cotinine level of
less than or equal to 50 microg/L). From this data, the absolute benefit increase was calculated
to be 8.7% and number of patients needed to treat with bupropion hydrochloride in order for one
adolescent to be abstinent from cigarettes for at least seven days was calculated to be twelve (pvalue = .03). At twenty-six weeks, 6 of the remaining 58 subjects from the placebo group and 9
of the remaining 65 subjects from the 300mg Bupropion hydrochloride group, reported
abstinence of seven days. This report was confirmed with a measurement of exhaled carbon
monoxide of less than 10pmm. The ABI was calculated to be 3.2% with a NNT of 32 patients
(p-value = .28).
Table 2: Seven Day Point Prevalence Abstinence (Muramoto, 2007)

6 wks*
confirmed
by urine
cotinine
levels
26 wks*
confirmed
by
exhaled
CO

Placebo

Bupropion
hydrochloride
300mg

5 of 89

12 of 83

0.03

6 of 58

9 of 65

0.28

Pvalue

*Weeks following TQD (Target quit date)

CER

EER

RBI

ABI

NNT

5.60%

14.30%

154.40%

8.70%

12 pts

10.60%

13.80%

30.20%

3.20%

32 pts
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Bupropion hydrochloride safety was determined by the incidence of the most common
side effect reported: headache. While approximately 54% of the placebo group reported
experiencing a headache during or immediately following administration of bupropion
hydrochloride, only 44% of those receiving bupropion 300mg reported the same. The number
needed to harm was therefore negative (-10), indicating that for every ten patients not treated
with bupropion, one patient will experience a headache.
Table 3: Incidence of Side Effects
Intervention
Varenicline
Bupropion
hydrochloride

SE
Any

CER
EER
RRI
ARI
NNH
14.29% 57.14%
300% 42.85% 3 pts
54.40% 44.20% -18.80% -10.20% -10 pts

Headache

In the Faessel study, participants were broken up into a total of six groups. The subjects
were split into two groups based on weight, and then into three subgroups that either received a
low dose of varencline (.5 mg QD for the first week, .5 mg BID for the second week), a high
dose of varencline (.5 mg BID for the first week, 1 mg BID for the second week), or a placebo.
The high-body-weight group (>55 k) consisted of 35 subjects (65.7% male; 77.1% white; mean
age, 15.2 years). For the purpose of this paper, the main focus is on the difference in data
between the three subgroups from the high dose group. The data regarding the efficacy of the
intervention was presented with continuous data. Table 4 includes this data, as well as the
calculations from the data converted into dichotomous form. The reduction in the average
number of cigarettes smoked 16 days following initiation of pharmacotherapy in the high dose,
low dose, and placebo subgroups were 58.9%, 44.4%, and 13.1%, respectively. The absolute
benefit increase in the high-dose subgroup was 45.8%, with 3 patients needing to be treated with
the higher dose varencline in order for one adolescent to reduce the number of cigarettes smoked
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per day. In the low-dose group, ABI was 31.3%, with 4 patients needed to be treated. The study
did not include any p-values.
Table 4: Reduction in CPD with Varencline Therapy (Faessel, 2009)
Baseline
Placebo
Varencline
(high
dose)
Varencline
(low dose)

16 days

Reduction

8.4

7.3

13.1%

9.5

3.9

58.9%

9

5.1

44.4%

CER
13.1%
13.1%

EER
58.9%
44.4%

RBI
77.8%
70.5%

ABI
45.8%
31.3%

NNT
3 pts
4 pts

Safety of the before mentioned intervention was addressed by number of patients
reporting adverse events (AEs) and severity rating of such events. AEs were reported by
57.1% of subjects in both the high- and low-dose varencline subgroups and by 14.3% of
subjects in the placebo group. The most common AEs were nausea, headache, vomiting,
and dizziness. Of the AEs reported by at least one subject in any treatment group, 92%
were mild in intensity.5 Absolute risk increase in terms of these adverse events was
determined to be 42.85%, with only 3 patients needing to be treated in order for at least one
AE to occur.
The Rubenstein study was a randomized, open-label, 12-week trial, including
adolescent smokers who were assigned to receive either weekly counseling alone for 8
weeks or 8 weeks of counseling along with 6 weeks of nicotine nasal spray (NNS). Since
the intervention being tested was delivered via nasal spray and not a pill, no placebo was
used. Therefore, the study was not blind. Of the original 40 participants, 15 of 23 in the
NSS and counseling group, and 12 of 17 in the counseling alone group completed the
study, including follow-up.
The primary outcome measured was self-reported continuous abstinence for at least
7 days, validated by a CO concentration of less than 4 ppm. An intention to treat analysis
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was used to determine abstinence such that participants who did not complete the study
were considered to still be smoking. 6 At 12 weeks following initiation of counseling,
however, no subjects from either group had abstained from tobacco use. The mean
reduction in cigarettes smoked per day in the group receiving both the NNS and counseling
and the counseling only group was found to be 42% and 32%, respectively (p-value = .61).
Similarly, all other measurement of efficacy of the NNS, including cravings, withdrawal,
and self-rated addiction scale, failed to show statistical significance at twelve weeks (pvalues .49-.91).
Table 5: Nicotine Nasal Spray
p-value
CPD
Cotinine
Addiction

0.61
0.16
0.83

CER
32.0%
17.6%
35.8%

EER
42.0%
-30.9%
18.8%

RBI

ABI

31.3%
-276%
-47.5%

10.0%
-48.5%
-17%

NNT
10 pts
-3 pts
-6 pts

Addiction: self report based on scale of 1-100 (1 = No addiction)
CPD: Cigarettes per day (confirmed by exhaled CO < 4ppm)

Safety of NNS in the adolescent population was determined by ratings of adverse
effects. 38.9% of participants either “agreed” or “strongly agreed” with the statement “The
spray had lots of adverse effects”. The statistical significance of the incidence of such
effects cannot be determined since no placebo arm existed for comparison.
Discussion
All pharmacotherapy options discussed in this review have been proven to be safe
and effective in aiding adults in tobacco use cessation. Few studies, however, have
addressed these interventions in the adolescent population.
Overall limitations of these studies were largely due to problems related to the
population being studied. To begin with, it is illegal for minors to purchase cigarettes.
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Also, because the body is still undergoing significant growth and development during
adolescence, more potential adverse effects of pharmacotherapy exist in this population.
These adverse events can be related to immaturity of organ systems involved in metabolism
of medication and that of the target organ of the medication, the brain, in addition to
potentially halting or altering further growth and development. Since the subjects in these
studies were minors, it was necessary to obtain informed consent from both the subjects
and the subjects’ parents. The stigma associated with committing illegal activity in
addition to the potential risk of pharmacotherapy, greatly limits the size of the population
willing to participate in these studies. The smaller the population, the more likely it is that
any differences in outcome between the group that received the intervention and the group
that did not are due to coincidence. With the exception of the Muramoto study, the studies
included in this review did not include a large enough population for the results to have
significance.
The Rubenstein study, which investigated NNS as the intervention, originally
included only 40 subjects, only 27 of whom completed the study with follow-up.
Furthermore, selection bias was created by offering monetary incentive to participate in the
study, which may have also contributed to lack of motivation to quit, and therefore a lack
of compliance. Poor compliance, as noted by 43% use of the NNS by the end of treatment
despite continued tobacco use, is also attributed to the high incidence of adverse effects.6
In addition, the lack of a placebo arm of the study could have contributed to a measurement
bias. Subjects receiving the NNS may have felt compelled to report what they thought to
be a more socially desirable response. The absence of a placebo also makes it impossible
to determine whether the adverse effects were due to the delivery route of the nicotine, the
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nicotine itself, or bias. The study ultimately concluded that due to the intolerability of side
effects, NNS was not an efficacious intervention for smoking cessation in the population
studied. Due to the before mentioned limitations, however, this conclusion cannot
accurately be applied to the population of all adolescent tobacco users.
In addition to the small population included in the Faessel study, the fact that safety
and efficacy of Varencline therapy was not the primary focus of the investigation limited
the significance of the results. The primary limitation of this study was the short follow-up
time of sixteen days, an inadequate period of time in which to determine continued
effectiveness of the intervention. Number need to harm was found to be equal to number
needed to treat in the high dose arm of the study, and greater than number needed to treat in
the low dose arm. This finding suggests that varencline therapy is unlikely to aid in
cessation without also causing side effects. Similar to the Rubenstein study, however,
results of this study cannot be applied to all adolescent tobacco users because of the small
population size, insufficient follow-up, and the absence of p-values demonstrating that
observed differences were not due to coincidence. Of importance, this was the only study
in which the subjects were not asked to stop tobacco use during pharmacotherapy
administration.5
In contrast to the other two studies, Muramoto et al. demonstrated significantly
positive results for the use of Bupropion hydrochloride as a smoking cessation therapy in
an adolescent population. The difference in abstinence rates between the placebo group
and the group receiving Bupropion hydrochloride 300mg at six weeks was found to be
statistically significant (p-value = .03). The difference between the two groups at 26
weeks, however, was not significant (p-value = .28). In addition, a negative number
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needed to harm indicates that Bupropion actually reduces certain adverse effects associated
with nicotine withdrawal.
Study limitations included modification of the study protocol (follow-up shortened
from 52 weeks after the quit date to 26 weeks) to adjust for recruitment changes and a
prolonged accrual period. In addition, losses to follow-up made up more than 20% of the
initial participants and no intention to treat analysis was performed. Furthermore, it was
determined that confirmation of abstinence with urine cotinine levels was more accurate
than confirmation with exhaled levels of CO; however, urine cotinine was only measured at
weeks 1 and 6.4
Conclusion
Only the Muramoto study investigating the safety and efficacy of Bupropion
hydrochloride confirmed results with enough significance to have implications for the
larger population of adolescent cigarette smokers. This study demonstrates that SR
bupropion hydrochloride at 300 mg/d plus brief behavioral counseling has short-term
efficacy in helping adolescent smokers quit, without significant adverse events. Six weeks
of pharmacotherapy was determined to be too short, however, as many subjects later
relapsed.4 While further investigation into the ideal length of therapy is still needed, it is
reasonable to recommend the use of Bupropion hydrochloride for smoking cessation in
adolescents who have failed conventional methods of quitting. At this time, there is not
enough evidence to suggest that either nicotine nasal spray or varencline is a safe or
effective therapy for smoking cessation in the adolescent population.

